SERPINA5 inhibits tumor cell migration by modulating the fibronectin-integrin β1 signaling pathway in hepatocellular carcinoma

Molecular Oncology

Volumn 8, Issue 2, 2014, Pages 366-377

  Jing, Ying ^a,b   Jia, Deshui ^b   Wong, Chun Ming ^c   Oi Lin Ng, Irene ^c   Zhang, Zhenfeng ^b   Liu, Li ^b   Wang, Qifeng ^b   Zhao, Fangyu ^b   Li, Jinjun ^b   Yao, Ming ^b   Wu, Xingzhong ^a   He, Xianghuo ^b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hepatocellular carcinoma; Metastasis; Migration; SERPINA5

Indexed keywords

BETA1 INTEGRIN; FIBRONECTIN; PROTEIN; SERPINA5 PROTEIN; UNCLASSIFIED DRUG; ONCOPROTEIN; SERPINA 5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CELL MIGRATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DOWN REGULATION; GENE DOSAGE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL TISSUE; HEPATOCELLULAR CARCINOMA CELL LINE; MIGRATION INHIBITION; ONCOGENE; REGULATORY MECHANISM; SERPINA 5 GENE; TUMOR CELL;

HEPATOCELLULAR CARCINOMA; METASTASIS; MIGRATION; SERPINA5;

ANTIGENS, CD29; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; NEOPLASM PROTEINS; PROTEIN C INHIBITOR; SIGNAL TRANSDUCTION;

EID: 84894365574     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.12.003     Document Type: Article

References (40)

1. Alimov A., Sundelin B., Wang N., Larsson C., Bergerheim U. Loss of 14q31-q32.2 in renal cell carcinoma is associated with high malignancy grade and poor survival. Int. J. Oncol. 2004, 25:179-185.
2. Asanuma K., Yoshikawa T., Hayashi T., Akita N., Nakagawa N., Hamada Y., Nishioka J., Kamada H., Gabazza E.C., Ido M., Uchida A., Suzuki K. Protein C inhibitor inhibits breast cancer cell growth, metastasis and angiogenesis independently of its protease inhibitory activity. Int. J. Cancer 2007, 121:955-965.
3. Bijsmans I.T., Smits K.M., de Graeff P., Wisman G.B., van der Zee A.G., Slangen B.F., de Bruine A.P., van Engeland M., Sieben N.L., Van de Vijver K.K. Loss of SerpinA5 protein expression is associated with advanced-stage serous ovarian tumors. Mod. Pathol. 2011, 24:463-470.
4. Buffart T.E., Carvalho B., van Grieken N.C., van Wieringen W.N., Tijssen M., Kranenbarg E.M., Verheul H.M., Grabsch H.I., Ylstra B., van de Velde C.J., Meijer G.A. Losses of chromosome 5q and 14q are associated with favorable clinical outcome of patients with gastric cancer. Oncologist 2012, 17:653-662.
5. Cao Y., Becker C., Lundwall A., Christensson A., Gadaleanu V., Lilja H., Bjartell A. Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues. Prostate 2003, 57:196-204.
6. Castello R., Landete J.M., Espana F., Vazquez C., Fuster C., Almenar S.M., Ramon L.A., Radtke K.P., Estelles A. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer. Thromb. Res. 2007, 120:753-762.
7. Caswell P.T., Spence H.J., Parsons M., White D.P., Clark K., Cheng K.W., Mills G.B., Humphries M.J., Messent A.J., Anderson K.I., McCaffrey M.W., Ozanne B.W., Norman J.C. Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Dev. Cell 2007, 13:496-510.
8. Cui J.F., Liu Y.K., Zhang L.J., Shen H.L., Song H.Y., Dai Z., Yu Y.L., Zhang Y., Sun R.X., Chen J., Tang Z.Y., Yang P.Y. Identification of metastasis candidate proteins among HCC cell lines by comparative proteome and biological function analysis of S100A4 in metastasis invitro. Proteomics 2006, 6:5953-5961.
9. Fortenberry Y.M., Brandal S., Bialas R.C., Church F.C. Protein C inhibitor regulates both cathepsin L activity and cell-mediated tumor cell migration. Biochim. Biophys. Acta 2010, 1800:580-590.
10. Francis R.B., Thomas W. Behaviour of protein C inhibitor in intravascular coagulation and liver disease. Thromb. Haemost. 1984, 52:71-74.
11. Fuchs B.C., Fujii T., Dorfman J.D., Goodwin J.M., Zhu A.X., Lanuti M., Tanabe K.K. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res. 2008, 68:2391-2399.
12. Geiger M. Protein C inhibitor, a serpin with functions in- and outside vascular biology. Thromb. Haemost. 2007, 97:343-347.
13. Genda T., Sakamoto M., Ichida T., Asakura H., Kojiro M., Narumiya S., Hirohashi S. Cell motility mediated by rho and Rho-associated protein kinase plays a critical role in intrahepatic metastasis of human hepatocellular carcinoma. Hepatology 1999, 30:1027-1036.
14. Han S., Khuri F.R., Roman J. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res. 2006, 66:315-323.
15. Huntington J.A., Li W. Structural insights into the multiple functions of protein C inhibitor. Cell Mol. Life Sci. 2009, 66:113-121.
16. Jackson T.P., Cooper S.T., Church F.C. Assessment of the interaction between urokinase and reactive site mutants of protein C inhibitor. J.Protein Chem. 1997, 16:819-828.
17. Jia D., Wei L., Guo W., Zha R., Bao M., Chen Z., Zhao Y., Ge C., Zhao F., Chen T., Yao M., Li J., Wang H., Gu J., He X. Genome-wide copy number analyses identified novel cancer genes in hepatocellular carcinoma. Hepatology 2011, 54:1227-1236.
18. Jia D., Yan M., Wang X., Hao X., Liang L., Liu L., Kong H., He X., Li J., Yao M. Development of a highly metastatic model that reveals a crucial role of fibronectin in lung cancer cell migration and invasion. BMC Cancer 2010, 10:364.
19. Kaspar M., Zardi L., Neri D. Fibronectin as target for tumor therapy. Int. J. Cancer 2006, 118:1331-1339.
20. Laurell M., Christensson A., Abrahamsson P.A., Stenflo J., Lilja H. Protein C inhibitor in human body fluids. Seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system. J.Clin. Invest. 1992, 89:1094-1101.
21. Lee T.K., Poon R.T., Yuen A.P., Ling M.T., Kwok W.K., Wang X.H., Wong Y.C., Guan X.Y., Man K., Chau K.L., Fan S.T. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin. Cancer Res. 2006, 12:5369-5376.
22. Li Y., Tian B., Yang J., Zhao L., Wu X., Ye S.L., Liu Y.K., Tang Z.Y. Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive invivo selection and studies on metastatic characteristics. J.Cancer Res. Clin. Oncol. 2004, 130:460-468.
23. Milner R., Crocker S.J., Hung S., Wang X., Frausto R.F., del Zoppo G.J. Fibronectin- and vitronectin-induced microglial activation and matrix metalloproteinase-9 expression is mediated by integrins alpha5beta1 and alphavbeta5. J.Immunol. 2007, 178:8158-8167.
24. Mitra S.K., Schlaepfer D.D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell Biol. 2006, 18:516-523.
25. Ohnishi T., Hiraga S., Izumoto S., Matsumura H., Kanemura Y., Arita N., Hayakawa T. Role of fibronectin-stimulated tumor cell migration in glioma invasion invivo: clinical significance of fibronectin and fibronectin receptor expressed in human glioma tissues. Clin. Exp. Metastasis 1998, 16:729-741.
26. Pankov R., Yamada K.M. Fibronectin at a glance. J.Cell Sci. 2002, 115:3861-3863.
27. Pehlivan D., Gunduz E., Gunduz M., Nagatsuka H., Beder L.B., Cengiz B., Rivera R.S., Fukushima K., Palanduz S., Ozturk S., Yamanaka N., Shimizu K. Loss of heterozygosity at chromosome 14q is associated with poor prognosis in head and neck squamous cell carcinomas. J.Cancer Res. Clin. Oncol. 2008, 134:1267-1276.
28. Rehault S.M., Zechmeister-Machhart M., Fortenberry Y.M., Malleier J., Binz N.M., Cooper S.T., Geiger M., Church F.C. Characterization of recombinant human protein C inhibitor expressed in Escherichia coli. Biochim. Biophys. Acta 2005, 1748:57-65.
29. Sengupta S., Nandi S., Hindi E.S., Wainwright D.A., Han Y., Lesniak M.S. Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model. Neoplasia 2010, 12:837-847.
30. Sherbet G.V., Tindle M.E., Stidolph S. Fibronectin in human astrocytomas grown in tissue culture. Anticancer Res. 1982, 2:251-254.
31. Shirk R.A., Elisen M.G., Meijers J.C., Church F.C. Role of the H helix in heparin binding to protein C inhibitor. J.Biol. Chem. 1994, 269:28690-28695.
32. Sil H., Sen T., Chatterjee A. Fibronectin-integrin (alpha5beta1) modulates migration and invasion of murine melanoma cell line B16F10 by involving MMP-9. Oncol. Res. 2011, 19:335-348.
33. Speleman F., Kumps C., Buysse K., Poppe B., Menten B., De Preter K. Copy number alterations and copy number variation in cancer: close encounters of the bad kind. Cytogenet. Genome Res. 2008, 123:176-182.
34. Stief T.W., Radtke K.P., Heimburger N. Inhibition of urokinase by protein C-inhibitor (PCI). Evidence for identity of PCI and plasminogen activator inhibitor 3. Biol. Chem. Hoppe Seyler 1987, 368:1427-1433.
35. Suzuki K., Hayashi T. Protein C and its inhibitor in malignancy. Semin. Thromb. Hemost. 2007, 33:667-672.
36. Suzuki K., Nishioka J., Hashimoto S. Protein C inhibitor. Purification from human plasma and characterization. J.Biol. Chem. 1983, 258:163-168.
37. Thorstensen L., Qvist H., Nesland J.M., Giercksky K.E., Lothe R.A. Identification of two potential suppressor gene regions on chromosome arm 14q that are commonly lost in advanced colorectal carcinomas. Scand. J. Gastroenterol. 2001, 36:1327-1331.
38. van Dekken H., Geelen E., Dinjens W.N., Wijnhoven B.P., Tilanus H.W., Tanke H.J., Rosenberg C. Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas. Cancer Res. 1999, 59:748-752.
39. Wakita T., Hayashi T., Nishioka J., Tamaru H., Akita N., Asanuma K., Kamada H., Gabazza E.C., Ido M., Kawamura J., Suzuki K. Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreased in renal cell carcinoma. Int. J. Cancer 2004, 108:516-523.
40. Yang J.D., Roberts L.R. Hepatocellular carcinoma: a global view. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:448-458.